PetMed Express Management Discusses Q1 2013 Results - Earnings Call Transcript

PetMed Express (PETS)

Q1 2013 Earnings Call

July 23, 2012 8:30 am ET

Executives

Bruce S. Rosenbloom - Chief Financial Officer, Principal Accounting Officer and Treasurer

Menderes Akdag - Chief Executive Officer, President, Director and Member of Investment Committee

Analysts

Kevin K. Ellich - Piper Jaffray Companies, Research Division

Mitchell O. Bartlett - Craig-Hallum Capital Group LLC, Research Division

Erin E. Wilson - BofA Merrill Lynch, Research Division

Michael A. Kupinski - Noble Financial Group, Inc., Research Division

Anthony C. Lebiedzinski - Sidoti & Company, LLC

Ross Taylor - CL King & Associates, Inc.

Presentation

Operator

Welcome to the PetMed Express, Incorporated Doing Business as 1-800-PetMeds Conference Call to review the financial results for the first fiscal quarter ended on June 30, 2012. At the request of the company, this conference call is being recorded.

Founded in 1996, 1-800-PetMeds is America's Largest Pet Pharmacy, delivering prescription and nonprescription pet medications and other health products for dogs and cats direct to the consumer. 1-800-PetMeds markets its products through national television, online, direct mail and print advertising campaigns, which direct consumers to order by phone or on the Internet and aim to increase the recognition of the PetMeds family of brand names. 1-800-PetMeds provides an attractive alternative for obtaining pet medication in terms of convenience, price, ease of ordering and rapid home delivery.

At this time, I would like to turn the conference call over to the company's Chief Financial Officer, Mr. Bruce Rosenbloom. And sir, you may begin.

Bruce S. Rosenbloom

Thank you. I'd like to welcome everybody here today. [Operator Instructions]

Also, certain information that will be included in this press conference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or the Securities and Exchange Commission that may involve a number of risks and uncertainties. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

NovoCure, NextEra, O'Reilly: 'Mad Money' Lightning Round (7/7/17)